A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Completed · Phase 3 · NCT06047548
Conditions: Overweight, Obesity
At a glance
- Research payments reported, 2025
- $5.9M
- U.S. investigators named
- 24
- Sites paid
- 22
- Planned or actual enrollment
- 441
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (drug)
- Dates
- Started 2023-09-20; completion 2026-01-20
- Results posted
- Not yet
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
From ClinicalTrials.gov, last updated 2026-03-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5.9M in research payments for this study in 2025 (46 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Michael S. Vaughn, M.D. Family Medicine · Birmingham, AL
- Hanid Audish, DO Family Medicine · Spring Valley, CA
- Jeffrey S. Overcash, MD Emergency Medicine · Chula Vista, CA
- Bradley M. Block, MD Family Medicine · Oviedo, FL
- Lazaro R. Diaz-nunez, MD Family Medicine · Naples, FL
- Dwight D. Blake, MD Internal Medicine · Union City, GA
- Cindy H. Pau, MD Endocrinology & Diabetes · Honolulu, HI
- Anuj Bhargava, MD Endocrinology & Diabetes · West Des Moines, IA
- Kevin Prier Internal Medicine · Idaho Falls, ID
- Mohan K. Kesani, M.D. Cardiology · Munster, IN
- Harold E. Bays, MD Endocrinology & Diabetes · Louisville, KY
- Demetri W. Marshall, M.D. Family Medicine · Port Gibson, MS
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Lisa B. Connery, M.D. Family Medicine · Norman, OK
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
- Obadias Marquez, MD Internal Medicine · Ooltewah, TN
- Sumana Gangi, M.D Endocrinology & Diabetes · Mesquite, TX
- Deborah B. Horn, DO Family Medicine · Bellaire, TX
- Julio Rosenstock, M.D. Endocrinology & Diabetes · Dallas, TX
- Madhavi Rudraraju, M.D. Hepatology · San Antonio, TX
- Daniel Santillano, MD Internal Medicine · San Antonio, TX
- Michelle D. Welch, MD Endocrinology & Diabetes · Shavano Park, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sky Clinical Research Network Group $1.1M
- Velocity Clinical Research Inc $435,602
- David Fitzpatrick MD DBA E West Med Rsrch $386,945
- Iowa Diabetes and Endocrinology Rsrch Cntr $374,531
- Rocky Mountain Clinical Research LLC $368,663
- Asha Clinical Research-Munster LLC $343,457
- Encompass Clinical Research $302,529
- New Horizon Research Center $302,167
- Alliance for Multispecialty Research Lls $296,994
- Compass Research East LLC $280,099
- Consano Clinical Research LLC $279,288
- Louisville Metabolic $269,734
- University of Texas Health $263,780
- Southern Endocrinology Associates PA $246,520
- Pinnacle Clinical Research LLC $227,626
- Cahaba Research $221,401
- Wr Clinsearch LLC $217,249
- $615
- Cleveland Clinic, OH $298
- Ut MD Anderson Cancer Center $266
- Clinsearch LLC $173
- Diabetes and Glandular Disease Ctr $63
- Charter Research LLC $4
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.